Crossmark

Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu

Crossref DOI link: https://doi.org/10.1186/s12913-024-11632-6

Published Online: 2024-09-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Xiaoxing

Zhou, Tingting

Zhou, Jing

Zhang, Doudou

Yang, Yili

Pan, Jay https://orcid.org/0000-0001-9501-1535
License Information

Text and Data Mining valid from 2024-09-27

Version of Record valid from 2024-09-27
More Information

Article History

Received: 24 March 2024

Accepted: 23 September 2024

First Online: 27 September 2024

Declarations

:

: All participants involved in this study provided written informed consent prior to their participation. This project was approved by the Medical Ethics Review Board, Sichuan University (Approval number: K2020027).

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below